EncrypGen

Coconut Creek, Florida, United States

Genetic Disorders Security & Privacy Biotech

Founded in 2017, the company first demonstrated its prototype in May 2017 at the Bio-IT World conference in Boston. With angel investment and a limited token sale of its $DNA utility coin in June 2017, the product was finalized and launched, as announced in The Scientist magazine, November 6, 2018 as the worldâ€™s first blockchain-mediated free market for genetic data. Since then, its community of supporters and users has grown virally, and various partnerships and platform developments have poised the company for consumer growth. It remains the only free market for genomic data powered by blockchain, and is committed to democratizing and decentralizing science (De-Sci), allowing individuals to make choices and benefit monetarily through their contributions to research. To find out how weâ€™re doing, take a look at our blog.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out EncrypGen on @MedStartr Today #GeneticDisorders #SecurityPrivacy #Biotech #MedMo #MedStartrVentures

https://www.medstartr.ai/s/XTtTVOEm7HM

Get Involved in EncrypGen

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2018
Website: encrypgen.com

Technologies

Platform

🌐Website

What do you think of EncrypGen?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.